Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants

NCT00937521 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00937521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00937521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
February 29, 2012
Enrollment
1,507 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal infections, meningococcal meningitis